Tiagabine
| Clinical data | |
|---|---|
| Pronunciation | /taɪˈæɡəbiːn/ | 
| Trade names | Gabitril | 
| AHFS/Drugs.com | Monograph | 
| MedlinePlus | a698014 | 
| Pregnancy category | 
 | 
| Routes of administration | By mouth | 
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 90–95% | 
| Protein binding | 96% | 
| Metabolism | Hepatic (CYP450 system, primarily CYP3A) | 
| Onset of action | Tmax = 45 min | 
| Elimination half-life | 5–8 hours | 
| Excretion | Fecal (63%) and renal (25%) | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C20H25NO2S2 | 
| Molar mass | 375.55 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
| (verify) | |
Tiagabine, sold under the brand name Gabitril, is an anticonvulsant medication produced by Cephalon that is used in the treatment of epilepsy. The drug is also used off-label in the treatment of anxiety disorders including panic disorder.